Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC – Biogen

1. Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC  Biogen
2. Lecanemab may be safe to administer in community of older adults  Healio
3. Leqembi’s Real-World Benefits, Risks Coming Into Focus in Ongoing Studies, Clinical Practice  Precision Medicine Online
4. Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025  Yahoo Finance
5. Biogen’s Alzheimer’s Innovation Pipeline: Lecanemab and BIIB080 as Catalysts for Long-Term Growth  AInvest

Continue Reading